EFFICACY AND SAFETY OF FENOFIBRATE 160 MG IN COMBINATION WITH PRAVASTATIN 40 MG IN TYPE 2 DIABETIC PATIENTS WITH COMBINED HYPERLIPIDEMIA AND WITHOUT CARDIOVASCULAR DISEASE

被引：0

作者：

Farnier, Michel ^{[1
]}

Steinmetz, Armin ^{[1
]}

Retterstol, Kjetil ^{[1
]}

Dluzniewski, Miroslaw ^{[1
]}

Csazar, Albert ^{[1
]}

机构：

[1] Point Med, Dijon, France

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2010年 / 55卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1076-110

引用

页数：1

共 50 条

[1] Attainment of cholesterol goals with Fenofibrate 160 mg/Pravastatin 40 mg Therapy in Type 2 Diabetic patients with combined hyperlipidemia in primary prevention, not at goal on Simvastatin 20 mg
Farnier, M.
Dluzniewski, M.
Csazar, A.
Steinmetz, A.
Retterstol, K.
EUROPEAN HEART JOURNAL, 2010, 31 : 390 - 390
[2] Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy
Farnier, Michel
Ducobu, Jean
Bryniarski, Leszek
AMERICAN JOURNAL OF CARDIOLOGY, 2010, 106 (06): : 787 - 792
[3] Efficacy and safety of the combination of fenofibrate 160mg/pravastin 40mg in type 2 diabetic patients in primary prevention with mixed hypercholesterolemia
Farnier, M.
Steinmetz, A.
Retterstol, K.
Dluzniewski, M.
Csazar, A.
DIABETES & METABOLISM, 2010, 36 : A95 - A95
[4] Comparative efficacy and safety of Fenofibrate/Pravastatin/Ezetimibe therapy and Simvastatin/Ezetimibe therapy in Type 2 Diabetic patients with combined hyperlipidemia and cardiovascular disease
Farnier, M.
Retterstol, K.
Dluzniewski, M.
Csazar, A.
Steinmetz, A.
EUROPEAN HEART JOURNAL, 2010, 31 : 601 - 601
[5] Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160 mg/40 mg in Patients with Mixed Hyperlipidaemia A Pooled Analysis from a Database of Clinical Trials
Farnier, Michel
Marcereuil, David
De Niet, Sophie
Ducobu, Jean
Steinmetz, Armin
Retterstol, Kjetil
Bryniarski, Leszek
Csaszar, Albert
Vanderbist, Francis
CLINICAL DRUG INVESTIGATION, 2012, 32 (04) : 281 - 291
[6] Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160 mg/40 mg in Patients with Mixed HyperlipidaemiaA Pooled Analysis from a Database of Clinical Trials
Michel Farnier
David Marcereuil
Sophie De Niet
Jean Ducobu
Armin Steinmetz
Kjetil Retterstøl
Leszek Bryniarski
Albert Császár
Francis Vanderbist
Clinical Drug Investigation, 2012, 32 : 281 - 291
[7] Comparative efficacy of fenofibrate/pravastatin/ezetimibe and simvastatin/ezetimibe therapies in type 2 diabetic patients with combined hyperlipidaemia and cardiovascular disease
Farnier, M.
Steinmetz, A.
Csaszar, A.
Retterstol, K.
Dluzniewski, M.
DIABETOLOGIA, 2010, 53
[8] Fixed-Dose Combination Fenofibrate/Pravastatin 160/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study
Farnier, Michel
Steinmetz, Armin
Retterstol, Kjetil
Csaszar, Albert
CLINICAL THERAPEUTICS, 2011, 33 (01) : 1 - 12
[9] Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy
Farnier, Michel
Ducobu, Jean
Bryniarski, Leszek
CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (11) : 2165 - 2173
[10] Efficacy and safety of pravastatin 40 mg day in Japanese patients with heterozygous familial hypercholesterolemia
Mabuchi, H
Matsuzawa, Y
Saito, Y
Gunji, A
ATHEROSCLEROSIS, 1999, 144 : 194 - 194

← 1 2 3 4 5 →